ArticleJournal for immunotherapy of cancer2020

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.

Sarah Abou Alaiwi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.